Uncategorized
Clearside Biomedical secures $16 million in Series B financing
Clearside Biomedical has announced the closure of a $16 million Series B financing. The gain includes new investor, RusnanoMedInvest, in addition to current investors Hatteras Venture Partners, Santen Pharmaceuticals, Mountain Group Capital and Georgia Research Alliance Venture Fund, according to a company press release.